In a global, phase III clinical trial labeled LASER301, the effectiveness of lazertinib was compared against gefitinib in treatment-naïve NSCLC patients with EGFR mutations, specifically those with exon 19 deletion (ex19del) or L858R mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.